Homepage-NV

Reven hits back, opposing SEC’s motion for injunctive relief. Read more here.

Reven

Pharmaceuticals

Launching a new generation of pharmacological solutions that target the root cause of diseases by restoring immune system homeostasis.

RJX by Reven

RJX is a stand-alone drug and a flexible formulation developed with a proprietary process to target areas of immunologic function without the need for stabilizers and preservatives.

“Our goal is to impact multiple disease indications stemming from inflammation ranging from cancer to cardiovascular disease in the same way antibiotics impacted infectious disease when they were discovered nearly a century ago.”